Skip to content
Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

Get the podcast

MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It ca

The Audio Journal of Oncology

MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It came from results of the De-ESCALaTE HPVstudy that found patients with low-risk head and neck cancer who tested positive for human papilloma virus (HPV+) did better if they had been treated with standard platinum-based chemotherapy (added their radiotherapy) rather than the epidermal growth factor receptor (EGFR) inhibitor cetuximab.

https://cslide.ctimeetingtech.com/esmo2018/attendee/confcal/session/calendar?q=+LBA9_PR

Phase three trials needed

“One of the big lessons is that you really need phase three trials—even when treatments are already approved—as in [the] case [of] head and neck cancer,” said Hisham Mehanna PhD BMed Sci FRCS, Chair of Head and Neck Surgery at the Institute for Head and Neck Studies Education in the University of Birmingham, UK. “You need phase three trials to compare new treatments to standards of care to really be able to take [them] into the clinic,” he told the Audio Journal of Oncology. “Clinical practice should not be changed without these phase three trials.”

Detriment from cetuximab

TheDe-ESCALaTE HPV study—reported at ESMO by Mehanna and his colleagues—found there had been “significant detriment from the use of cetuximab instead of cisplatin in terms of tumor control and no benefit in terms of reduced toxicity. They concluded that: “Cisplatin and radiotherapy remained the standard of care in this setting.”

Tags

cetuximab to de-escalate oropharyngeal cancer theraphead and neck cancer cetuximabHPV positive oropharyngeal canceroropharyngeal cancer

Next in ESMO 2018

All 11 interviews

Interview 2 of 11

Which New Combination for Metastatic Renal Cell Cancer?

Which New Combination for Metastatic Renal Cell Cancer?

MUNICH—A leading European oncologist acknowledged the impressive life-extending potential of new drug combinations for metastatic renal cell carcinoma discussed at the 2018 annual congress of the Euro

12 November 2018

Related Episodes

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:

12 Nov 2026
4 min
Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.

5 Nov 2026
10 min
James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin PhD FRCP F Med Sci, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.

2 Nov 2026
15 min